• New Insights from SABCS 2024: Biomarkers and Pembrolizumab in TNBC

    At the San Antonio Breast Cancer Symposium (SABCS) 2024, Joyce O’Shaughnessy presented findings from the KEYNOTE-522 trial, a phase 3 study evaluating pembrolizumab in combination with chemotherapy for early-stage triple-negative…

  • Study Highlights Socioeconomic Barriers in Access to Allo-HCT for AML Patients

    A study published in Blood on November 5, 2024, reveals how socioeconomic factors influence access to allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) patients. The findings indicate…

  • New Potential Treatment for Sickle Cell Disease: IMA001 Shows Promise

    Presented on November 5, 2024, new research highlights the potential of IMA001 as a novel therapeutic approach for Sickle Cell Disease (SCD). The study demonstrated that IMA001 significantly reduced red…

  • New Findings on Blinatumomab for Childhood B-Cell Acute Lymphoblastic Leukemia (B-Cell ALL)!

    On December 7, 2024, a phase 3 trial published in The New England Journal of Medicine provided compelling evidence on the addition of blinatumomab to chemotherapy in children with newly…

  • News of ASH：Application of the Ketogenic Diet in CAR-T Therapy

    The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the latest developments, Hematology Frontier presents the News of ASH series, offering key takeaways…

  • Unlocking the Prognostic Power of ctDNA in Colorectal Cancer: Insights from a Landmark Study

    The CALGB/SWOG 80702 trial enrolled 2,526 patients with resected adenocarcinoma of the colon without metastatic disease. Of these, 1,752 patients consented to biospecimen collection, leading to the successful banking of…

  • News of ASH：Gut Microbiota and CAR-T Therapy

    The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided valuable insights into fundamental research, innovative therapies, and disease management in hematology. To distill the essence of ASH and capture the latest advancements in the field, Hematology Frontier…

  • News of ASH：Overview of Acute Myeloid Leukemia Research Advances in 2024

    The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, gathering over 30,000 experts and scholars from around the world. This year’s conference featured numerous carefully curated sessions, providing profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the key findings from ASH 2024, Hematology Frontier presents the…